Other Sources Fund Early-Stage Alzheimer’s Research As Pharma Favors Later Stages

Could Approval Of Biogen’s Aducanumab Improve Risk Tolerance?

 
• By Mandy Jackson
  
Computer illustration of amyloid plaques amongst neurons
As Alzheimer's drug development diversifies beyond amyloid, government and nonprofit funders step in to de-risk early clinical programs • Source: Alamy

More from Clinical Trials

More from R&D